
Gary Glick (Scorpion Therapeutics)
Serial entrepreneur Gary Glick sells another one of his startups for $229M — this time to an unlikely buyer
Gary Glick has proven himself, time and again, a nifty startup artist. After selling Lycera to Celgene, he held a streak for IFM Therapeutics — carving a plate of inflammation programs each time and turning the resulting subsidiary over to Big Pharma, while keeping the core discovery unit — and more recently lined up $270 million for precision oncology work at Scorpion.
His latest deal, though, looks a bit different.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters